Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Free meds could boost quit rates in stroke survivors

NCT ID NCT00962988

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether giving stroke or TIA survivors free smoking-cessation medications (like nicotine patches, bupropion, or varenicline) for 12 weeks helps them quit smoking more effectively than just giving a prescription. The study will compare quit rates and cost-effectiveness between the two approaches. Participants are daily smokers who have had a stroke or TIA and are willing to set a quit date.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Free smoking cessation pharmacotherapy (nicotine patch, bupropion, or varenicline)
What this could lead to
If effective, providing free cessation medications could significantly increase quit rates among stroke survivors, reducing their risk of future strokes and improving long-term health.
What could go wrong
The trial is relatively small and focuses on a specific high-risk group, so results may not apply to all smokers. Also, quitting smoking is difficult, and even with free medication, many participants may relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

194 people

The number who actually took part.

Start date

Dec 2009

Finished

Apr 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is a current daily smoker (one cigarette per day in the month preceding the visit to the Stroke Prevention Clinic) 2. Patient has been diagnosed with TIA or stroke at any point in time 3. Patient is able, in the opinion of the neurologist, to comprehend and participate in the smoking cessation interventions 4. Patient is 18 years of age or older 5. Patient is willing to set a quit date 6. Patient willing to travel to study centre for follow-up visits 7. Patient is willing to provide informed consent Exclusion Criteria: 1. Patient is unable to understand English or French 2. Patient is not willing to use pharmacotherapy to quit 3. Patient has been using smoking cessation medication for more than 6 weeks directly prior to clinic visit or hospital admission. 4. Patient is pregnant, lactating or planning to become pregnant during the study period 5. Patient has contraindication(s) to all of the following smoking cessation medications: * Nicotine replacement therapy (allergy to adhesive, serious cardiac arrhythmias (e.g., tachycardia), vasospastic disease (e.g., Buerger's disease, Prinzmetal's variant angina) * Bupropion (history of seizure disorder or head trauma; presently taking Wellbutrin; previous reaction to bupropion/Zyban/Wellbutrin; pre-existing or current eating disorder; taking anti-depressants, antipsychotics, corticosteroids, MAO inhibitors, theophylline, cocaine or diet pills; taking a quinalone antibiotic (e.g., ciprofloxacin, levoflozacin); currently using oral hypoglycemic product or insulin; severe hepatic impairment; CNS tumour; and * Varenicline (renal failure; use of cimetidine; previous reaction to varenicline)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebrovascular disorder Smoking Cessation stroke disorder transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular disorders Smoking cessation

Contacts and locations

Locations

  • Hamilton Health Sciences -Stroke Prevention Clinic

    Hamilton, Ontario, L8L 2X2, Canada

  • The Ottawa Hospital - Stroke Prevention Clinic

    Ottawa, Ontario, K1Y 4E9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.